Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 3, 2009, La Jolla Pharmaceutical Company (the "Company") received a letter from The Nasdaq Stock Market ("Nasdaq") notifying the Company that it is not in compliance with Nasdaq Marketplace Rule 4450(a)(3), which requires that the Company maintain a minimum of $10,000,000 in stockholders' equity for continued listing on The Nasdaq Global Market. This April 3, 2009 letter has no immediate effect on the listing of the Company's common stock.

The Company must provide Nasdaq with the Company's plan to regain compliance with Rule 4450(a)(3) by April 20, 2009. The Company is in the process of preparing such response and has not yet determined any specific actions to be taken to regain compliance with the continued listing standards. If Nasdaq does not accept the Company's plan to regain compliance with the continued listing standards, it will provide the Company with a written notification that its securities will be delisted from The Nasdaq Global Market. If the Company receives such notification, it may apply to move its listing to The Nasdaq Capital Market or appeal Nasdaq's delisting determination to a Nasdaq Listing Qualifications Panel.

---

Top of the Form